Update on melanocortin interventions for cachexia: Progress toward clinical application

Nutrition

Volumn 26, Issue 2, 2010, Pages 146-151

  DeBoer, Mark Daniel ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Anorexia; Cachexia; Ghrelin; MC4 R; Melanocortin

Indexed keywords

2 [2 [2 (5 BROMO 2 METHOXYPHENYL)ETHYL] 3 FLUOROPHENYL] 4,5 DIHYDRO 1H IMIDAZOLE; AGOUTI RELATED PROTEIN; CYTOKINE; FAT; HORMONE ANTAGONIST; MELANOCORTIN; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN ANTAGONIST; NBI 12I; NEUROPEPTIDE Y; PIPERAZINE DERIVATIVE; PROOPIOMELANOCORTIN; PYRROLIDINE DERIVATIVE; SNT 207707; SNT 209858; UNCLASSIFIED DRUG;

ANOREXIA; CACHEXIA; CANCER CACHEXIA; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; ENERGY EXPENDITURE; HEART FAILURE; HUMAN; LEAN BODY WEIGHT; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; UREMIA;

ANIMALS; ANOREXIA; CACHEXIA; DISEASE MODELS, ANIMAL; HUMANS; HYPOTHALAMUS; MELANOCORTINS; RECEPTOR, MELANOCORTIN, TYPE 4;

EID: 73649113084     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2009.07.003     Document Type: Review

References (51)

1. Tisdale M.J. Biology of cachexia. J Natl Cancer Inst 89 (1997) 1763-1773
2. DeBoer M.D., and Marks D.L. Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic disease. Nat Clin Pract Endocrinol Metab 2 (2006) 459-466
3. Marks D.L., Ling N., and Cone R.D. Role of the central melanocortin system in cachexia. Cancer Res 61 (2001) 1432-1438
4. Cone R.D. Anatomy and regulation of the central melanocortin system. Nat Neurosci 8 (2005) 571-578
5. Cheunsuang O., and Morris R. Astrocytes in the arcuate nucleus and median eminence that take up a fluorescent dye from the circulation express leptin receptors and neuropeptide Y Y1 receptors. Glia 52 (2005) 228-233
6. Cowley M.A., Pronchuk N., Fan W., Dinulescu D.M., Colmers W.F., and Cone R.D. Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat. Neuron 24 (1999) 155-163
7. Whitaker K.W., and Reyes T.M. Central blockade of melanocortin receptors attenuates the metabolic and locomotor responses to peripheral interleukin-1beta administration. Neuropharmacology 54 (2008) 509-520
8. Markison S., Foster A.C., Chen C., Brookhart G.B., Hesse A., Hoare S.R., et al. The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. Endocrinology 146 (2005) 2766-2773
9. Krakoff J., Ma L., Kobes S., Knowler W.C., Hanson R.L., Bogardus C., and Baier L.J. Lower metabolic rate in individuals heterozygous for either a frameshift or a functional missense MC4R variant. Diabetes 57 (2008) 3267-3272
10. Fan W., Boston B.A., Kesterson R.A., Hruby V.J., and Cone R.D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 385 (1997) 165-168
11. Farooqi I.S., Keogh J.M., Yeo G.S., Lank E.J., Cheetham T., and O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 348 (2003) 1085-1095
12. Farooqi I.S., Yeo G.S., Keogh J.M., Aminian S., Jebb S.A., Butler G., et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 106 (2000) 271-279
13. DeBoer M.D. Melanocortin interventions in cachexia: how soon from bench to bedside?. Curr Opin Clin Nutr Metab Care 10 (2007) 457-462
14. Thornton J.E., Cheung C.C., Clifton D.K., and Steiner R.A. Regulation of hypothalamic proopiomelanocortin mRNA by leptin in ob/ob mice. Endocrinology 138 (1997) 5063-5066
15. Hakansson M.L., Hulting A.L., and Meister B. Expression of leptin receptor mRNA in the hypothalamic arcuate nucleus-relationship with NPY neurones. Neuroreport 7 (1996) 3087-3092
16. Schwartz M.W., Seeley R.J., Woods S.C., Weigle D.S., Campfield L.A., Burn P., and Baskin D.G. Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes 46 (1997) 2119-2123
17. Scarlett J.M., Jobst E.E., Enriori P.J., Bowe D.D., Batra A.K., Grant W.F., et al. Regulation of Central Melanocortin Signaling by Interleukin-1{beta}. Endocrinology 148 (2007) 4217-4225
18. Scarlett J.M., Zhu X., Enriori P.J., Bowe D.D., Batra A.K., Levasseur P.R., et al. Regulation of agouti-related protein messenger ribonucleic acid transcription and peptide secretion by acute and chronic inflammation. Endocrinology 149 (2008) 4837-4845
19. Hayakawa T., Takanaga A., Tanaka K., Maeda S., and Seki M. Ultrastructure of the central subnucleus of the nucleus tractus solitarii and the esophageal afferent terminals in the rat. Anat Embryol (Berl) 206 (2003) 273-281
20. Ritter R.C. Gastrointestinal mechanisms of satiation for food. Physiol Behav 81 (2004) 249-273
21. Ruud J., and Blomqvist A. Identification of rat brainstem neuronal structures activated during cancer-induced anorexia. J Comp Neurol 504 (2007) 275-286
22. DeBoer M.D., Scarlett J.M., Levasseur P.R., Grant W.F., and Marks D.L. Administration of IL-1beta to the 4th ventricle causes anorexia that is blocked by agouti-related peptide and that coincides with activation of tyrosine-hydroxylase neurons in the nucleus of the solitary tract. Peptides 30 (2009) 210-218
23. Marty V., El Hachmane M., and Amedee T. Dual modulation of synaptic transmission in the nucleus tractus solitarius by prostaglandin E2 synthesized downstream of IL-1beta. Eur J Neurosci 27 (2008) 3132-3150
24. Zheng H., Patterson L.M., Phifer C.B., and Berthoud H.R. Brain stem melanocortinergic modulation of meal size and identification of hypothalamic POMC projections. Am J Physiol Regul Integr Comp Physiol 289 (2005) R247-R258
25. DeBoer M.D., Zhu X., Levasseur P.R., Inui A., Hu Z., Han G., et al. Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 149 (2008) 827-835
26. DeBoer M.D., Zhu X.X., Levasseur P., Meguid M.M., Suzuki S., Inui A., et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology 148 (2007) 3004-3012
27. DeBoer M.D. Emergence of ghrelin as a treatment for cachexia syndromes. Nutrition 24 (2008) 806-814
28. Knoll S., Zimmer S., Hinney A., Scherag A., Neubauer A., and Hebebrand J. Val103Ile polymorphism of the melanocortin-4 receptor gene (MC4R) in cancer cachexia. BMC Cancer 8 (2008) 85
29. Yang Y.K., Fong T.M., Dickinson C.J., Mao C., Li J.Y., Tota M.R., et al. Molecular determinants of ligand binding to the human melanocortin-4 receptor. Biochemistry 39 (2000) 14900-14911
30. Chen M., Cai M., Aprahamian C.J., Georgeson K.E., Hruby V., Harmon C.M., and Yang Y. Contribution of the conserved amino acids of the melanocortin-4 receptor in [corrected] [Nle4, D-Phe7]-alpha-melanocyte-stimulating [corrected] hormone binding and signaling. J Biol Chem 282 (2007) 21712-21719
31. Khoury M.J., Gwinn M., Yoon P.W., Dowling N., Moore C.A., and Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?. Genet Med 9 (2007) 665-674
32. Greenfield J.R., Miller J.W., Keogh J.M., Henning E., Satterwhite J.H., Cameron G.S., et al. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 360 (2009) 44-52
33. Bowe D.D., Scarlett J.M., Basra A.K., Steiner R.A., and Marks D.L. Blockade of central melanocortin signaling promotes accumulation of lean body mass in rodent models of chronic heart failure. J Investig Med 55 (2007) S77
34. Basra A.K., Scarlett J.M., Bowe D.D., Steiner R.A., and Marks D.L. Central melanocortin blockade attenuates cardiac cachexia in a rat model of chronic heart failure. J Investig Med 56 (2008) 229-230
35. Joppa M.A., Gogas K.R., Foster A.C., and Markison S. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice. Peptides 28 (2007) 636-642
36. von Haehling S., Lainscak M., Springer J., and Anker S.D. Cardiac cachexia: a systematic overview. Pharmacol Ther 121 (2009) 227-252
37. Anker S.D., Swan J.W., Volterrani M., Chua T.P., Clark A.L., Poole-Wilson P.A., and Coats A.J. The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J 18 (1997) 259-269
38. Anker S.D., Ponikowski P., Varney S., Chua T.P., Clark A.L., Webb-Peploe K.M., et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349 (1997) 1050-1053
39. Antman E.M., Hand M., Armstrong P.W., Bates E.R., Green L.A., Halasyamani L.K., et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 writing committee. Circulation 117 (2008) 296-329
40. Cheung W., Yu P.X., Little B.M., Cone R.D., Marks D.L., and Mak R.H. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 115 (2005) 1659-1665
41. Huang Q.H., Hruby V.J., and Tatro J.B. Role of central melanocortins in endotoxin-induced anorexia. Am J Physiol Regul Integr Comp Physiol 276 (1999) R864-R871
42. Wisse B.E., Frayo R.S., Schwartz M.W., and Cummings D.E. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 142 (2001) 3292-3301
43. Weyermann P., Dallmann R., Magyar J., Anklin C., Hufschmid M., Dubach-Powell J., et al. Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice. PLoS One 4 (2009) e4774
44. Cheung W.W., Kuo H.J., Markison S., Chen C., Foster A.C., Marks D.L., and Mak R.H. Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice. J Am Soc Nephrol 18 (2007) 2517-2524
45. Tran J.A., Jiang W., Tucci F.C., Fleck B.A., Wen J., Sai Y., et al. Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptor. J Med Chem 50 (2007) 6356-6366
46. Jiang W., Tucci F.C., Tran J.A., Fleck B.A., Wen J., Markison S., et al. Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor. Bioorg Med Chem Lett 17 (2007) 5610-5613
47. Chen C., Tucci F.C., Jiang W., Tran J.A., Fleck B.A., Hoare S.R., et al. Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. Bioorg Med Chem 16 (2008) 5606-5618
48. Nicholson J.R., Kohler G., Schaerer F., Senn C., Weyermann P., and Hofbauer K.G. Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice. J Pharmacol Exp Ther 317 (2006) 771-777
49. Vos T.J., Caracoti A., Che J.L., Dai M., Farrer C.A., Forsyth N.E., et al. Identification of 2-[2-[2-(5-bromo-2-methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H- imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. J Med Chem 47 (2004) 1602-1604
50. Trials for cachexia treatment. Available at: http://clinicaltrials.gov/ct2/results?term=cachexia&pg=4. Accessed June 30, 2009.
51. DeBoer M.D., and Marks D.L. Cachexia: lessons from melanocortin antagonism. Trends Endocrinol Metab 17 (2006) 199-204